Acumen Pharmaceuticals, Inc. (ABOS) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-03-26

Key Insights

Acumen Pharmaceuticals reported full year 2025 financial results, indicating progress for the company.
The company also announced a private placement completed on March 16, 2026, strengthening its cash position.
Acumen's updated corporate presentation highlights its cash, cash equivalents and marketable securities balance as of December 31, 2025.

Want the newest filings?

This analysis covers the filing from 2026-03-26. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-01-12

Acumen Pharmaceuticals, Inc. (ABOS) has updated its corporate presentation to include new nonclinical murine brain exposure data supporting its Enhanced Brain Delivery (EBD™) program, as well as updated views of previously presented fluid biomarker data from the Phase 1 INTERCEPT-AD study.
The company has also included its ACU234 program in the pipeline related to the EBD program, indicating further development of its drug candidates.
The filing suggests that Acumen Pharmaceuticals is actively updating investors on the progress of its clinical programs and pipeline, which could be of interest to potential investors.

Other reports for Acumen Pharmaceuticals, Inc.

Annual Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.